Plasma Profiling of Acute Myeloid Leukemia With Fever- and Infection-Related Complications During Chemotherapy-Induced Neutropenia

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2024 Oct 23

PMID 39441646

Authors

Iris C Kreft

Annemarie van de Geer

Eva R Smit

Carmen van der Zwaan

Floris P J van Alphen

Alexander B Meijer

Erfan Nur

Arie J Hoogendijk

Taco W Kuijpers

Maartje van den Biggelaar

Affiliations

Soon will be listed here.

Abstract

Background: Acute myeloid leukemia (AML) is a heterogenous and complex blood cancer requiring aggressive treatment. Early identification and prediction of the complications following treatment is vital for effective disease management.

Aims: We explored associations between plasma protein levels and fever- and infection-related complications in 26 AML patients during chemotherapy-induced neutropenia.

Material And Methods: Longitudinal plasma profiling was conducted using data-dependent mass spectrometry analysis.

Results: Mass spectrometry-based plasma profiling data correlated well with laboratory parameters, including C-reactive protein, and revealed a broader inflammation protein network associated with fever- and infection-related complications.

Discussion And Conclusion: These data indicate the potential of longitudinal plasma profiling in AML patients for identifying and predicting complications that may aid in improved disease monitoring and treatment.

Citing Articles

Plasma proteomes of acute myeloid leukemia patients treated with transfusions reveal signatures of inflammation and hemostatic dysregulation.

Smit E, Munoz Sandoval D, Kreft I, van der Meer P, van der Zwaan C, Voorberg J Transl Med Commun. 2025; 9(1):27.

PMID: 40078206 PMC: 11893646. DOI: 10.1186/s41231-024-00189-5.

References

Sui Y, Zhao Z, Zhang Y, Zhang T, Li G, Liu L . Fibrinogen-like Protein 1 as a Predictive Marker for the Incidence of Severe Acute Pancreatitis and Infectious Pancreatic Necrosis. Medicina (Kaunas). 2022; 58(12). PMC: 9785826. DOI: 10.3390/medicina58121753. View

Short N, Rytting M, Cortes J . Acute myeloid leukaemia. Lancet. 2018; 392(10147):593-606. PMC: 10230947. DOI: 10.1016/S0140-6736(18)31041-9. View

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

Cox J, Neuhauser N, Michalski A, Scheltema R, Olsen J, Mann M . Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011; 10(4):1794-805. DOI: 10.1021/pr101065j. View

Landry A, Docherty P, Ouellette S, Cartier L . Causes and outcomes of markedly elevated C-reactive protein levels. Can Fam Physician. 2017; 63(6):e316-e323. PMC: 5471098. View

Lowenberg B, Pabst T, Maertens J, Gradowska P, Biemond B, Spertini O . Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv. 2021; 5(4):1110-1121. PMC: 7903238. DOI: 10.1182/bloodadvances.2020003855. View

Akesson J, Hojjati S, Hellberg S, Raffetseder J, Khademi M, Rynkowski R . Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis. Nat Commun. 2023; 14(1):6903. PMC: 10616092. DOI: 10.1038/s41467-023-42682-9. View

Klastersky J, Paesmans M, Rubenstein E, Boyer M, Elting L, Feld R . The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18(16):3038-51. DOI: 10.1200/JCO.2000.18.16.3038. View

Janssen J, Lowenberg B, Manz M, Bargetzi M, Biemond B, Borne P . Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers (Basel). 2021; 13(4). PMC: 7914531. DOI: 10.3390/cancers13040672. View

10.

Zhang Y, Zhang J, Sheng H, Li H, Wang R . Acute phase reactant serum amyloid A in inflammation and other diseases. Adv Clin Chem. 2019; 90:25-80. DOI: 10.1016/bs.acc.2019.01.002. View

11.

van Eijkelenburg N, Rasche M, Ghazaly E, Dworzak M, Klingebiel T, Rossig C . Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. Haematologica. 2018; 103(9):1484-1492. PMC: 6119144. DOI: 10.3324/haematol.2017.187153. View

12.

Mo X, Su Z, Lei C, Chen D, Peng H, Chen R . Serum amyloid A is a predictor for prognosis of COVID-19. Respirology. 2020; 25(7):764-765. PMC: 7272841. DOI: 10.1111/resp.13840. View

13.

Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K . The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection. 2008; 36(5):396-407. DOI: 10.1007/s15010-008-7374-y. View

14.

Geyer P, Voytik E, Treit P, Doll S, Kleinhempel A, Niu L . Plasma Proteome Profiling to detect and avoid sample-related biases in biomarker studies. EMBO Mol Med. 2019; 11(11):e10427. PMC: 6835559. DOI: 10.15252/emmm.201910427. View

15.

Kelly R, Lasky-Su J, Yeung S, Stone R, Caterino J, Hagan S . Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One. 2018; 13(5):e0197049. PMC: 5955575. DOI: 10.1371/journal.pone.0197049. View

16.

Kyriazopoulou E, Leventogiannis K, Tavoulareas G, Mainas E, Toutouzas K, Mathas C . Presepsin as a diagnostic and prognostic biomarker of severe bacterial infections and COVID-19. Sci Rep. 2023; 13(1):3814. PMC: 9990570. DOI: 10.1038/s41598-023-30807-5. View

17.

Subbe C, Kruger M, Rutherford P, Gemmel L . Validation of a modified Early Warning Score in medical admissions. QJM. 2001; 94(10):521-6. DOI: 10.1093/qjmed/94.10.521. View

18.

Captur G, Moon J, Topriceanu C, Joy G, Swadling L, Hallqvist J . Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection. EBioMedicine. 2022; 85:104293. PMC: 9515404. DOI: 10.1016/j.ebiom.2022.104293. View

19.

Haeusler G, Garnham A, Li-Wai-Suen C, Clark J, Babl F, Allaway Z . Blood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia. Clin Transl Immunology. 2022; 11(5):e1383. PMC: 9113042. DOI: 10.1002/cti2.1383. View

20.

Kreft I, Hoogendijk A, van der Zwaan C, van Alphen F, Boon-Spijker M, Prinsze F . Mass spectrometry-based analysis on the impact of whole blood donation on the global plasma proteome. Transfusion. 2023; 63(3):564-573. DOI: 10.1111/trf.17254. View